November 1, 2021 -- Immatics plans to offer an update on its ACTengine IMA203 trial at the upcoming Society for Immunotherapy of Cancer (SITC) 2021 annual meeting in Washington, DC, November 12-13.
The company's ACTengine is a next-generation CD8ab T-cell receptor T-cell (TCR-T) approach used to develop T cell-redirecting cancer immunotherapies. The approach uses a patient's own T cells that are genetically engineered to express a novel, proprietary T-cell receptor directed against a defined cancer target. The modified T cells are then reinfused into the patient to attack the tumor, an approach also known as TCR-T.
The update will be delivered by Dr. Martin Wermke of the University Hospital Carl Gustav Carus in Dresden, Germany, in a presentation titled "Safety and Anti-Tumor Activity of TCR-Engineered Autologous, PRAME-Directed T Cells Across Multiple Advanced Solid Cancers at Low Doses," according to Immatics.
A second presentation delivered by the company's director of process development, Mamta Kalra, PhD, will update attendees on the company's next-generation CD8ab TCR-T approach, it said.